Cinven is an international private equity firm specializing in investments across Europe, focusing on building world-class global companies. With a sector-specific approach, the firm targets businesses requiring equity investments of 200 million or more, leveraging proven value enhancement strategies. Founded in 1977, Cinven operates from offices in key financial centers and manages capital for over 200 global investors.
- Biotechnology
- Pharmaceuticals
- Healthcare
- Technology
- Software
- Risk Management
- Procurement
- Supply Chain Management
- Specialty Chemicals
- Network Services
Leadership
| Name | Title | ||
|---|---|---|---|
| Julia Kahr | Partner |
in/julia-kahr-59a20a52
|
|
| Partner |
|
|
|
| Partner |
|
|
|
| Managing Director |
|
|
|
| Managing Director |
|
|
|
| Senior Principal |
|
|
|
| Senior Principal |
|
|
Recent Transactions involving Cinven
| Deal | Target | Platform | Buyer | Industry |
|---|---|---|---|---|
Cinven to sell minority stake in SYNLAB to financial investor Elliott |
SYNLAB |
CinvenElliott Investment Management |
Medical Diagnostics | |
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
||
|
|
|
|
The Lower and Middle Market M&A Platform
See how PrivSource can help you close more deals.
Learn more →